Clinical trials: Human Immunodeficiency Virus
HIV Infections
The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms
To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone. PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.
- Trial name
- NCT00002357
- Testing
- HBY 097, Zidovudine
- Where
- 6 sites in United States
- Volunteers
- 144 people
- Sponsor
- Hoechst Marion Roussel
Sarcoma, Kaposi, HIV Infections
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
- Trial name
- NCT00002137
- Testing
- Tecogalan sodium
- Where
- United States
- Sponsor
- Daiichi Pharmaceuticals
Infection, Human Immunodeficiency Virus
Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing
A phase I absolute bioavailability study of BMS-626529 following oral and intravenous dosing
- Trial name
- NCT02805556
- Testing
- BMS-663068, BMS-626529
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
To characterize the safety and efficacy of fixed doses of MDL 28,574A administered alone and in combination with zidovudine ( AZT ) in patients with asymptomatic or mildly symptomatic HIV infection.
- Trial name
- NCT00002151
- Testing
- Celgosivir hydrochloride
- Where
- 24 sites in United States
- Volunteers
- 200 people
- Sponsor
- Hoechst Marion Roussel
HIV Infections
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day…
- Trial name
- NCT00294372
- Testing
- BILR 355 BS
- Where
- 11 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection
This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the drug causes.
- Trial name
- NCT00002453
- Testing
- Tenofovir disoproxil fumarate
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Gilead Sciences
HIV Infection, Infection, Human Immunodeficiency Virus
A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects
This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen administered either twice-daily or…
- Trial name
- NCT00363142
- Testing
- Half-boosted Fosamprenavir, Full Boosted Fosamprenavir
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 211 people
- Sponsor
- GlaxoSmithKline
HIV
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents
The primary objective of this study is to evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected virologically suppressed adolescents 12 to < 18 years of…
- Trial name
- NCT02276612
- Testing
- E/C/F/TAF
- Where
- 7 sites in United States, South Africa
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Candidiasis, Oral, HIV Infections
An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.
To assess the efficacy and safety of itraconazole oral solution in HIV-seropositive patients with oropharyngeal candidiasis that is refractory to fluconazole.
- Trial name
- NCT00002133
- Testing
- Itraconazole
- Where
- 18 sites in United States
- Sponsor
- Janssen, LP
HIV Infections
Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
This study examined the effects of two commonly prescribed HIV drugs on the way the body metabolizes glucose, insulin and fat.
- Trial name
- NCT00135434
- Testing
- Atazanavir/Ritonavir/Lopinavir/ritonavir
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients
The purpose of this study is to examine how the immune systems of HIV-infected patients react to 2 anti-HIV drug combinations.
- Trial name
- NCT00002448
- Testing
- Ritonavir, Efavirenz, Saquinavir
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients
To identify doses of fozivudine tidoxil that are well tolerated and produce measurable antiviral activity. To identify the adverse event profile that defines the maximum tolerated dose.
- Trial name
- NCT00002385
- Testing
- Fozivudine tidoxil
- Volunteers
- 60 people
- Sponsor
- Anderson Clinical Research
HIV Infections
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and…
- Trial name
- ENTRANCE (NCT07053384)
- Testing
- VH3810109, Fostemsavir (FTR), SOC INSTI-based ART
- Where
- 41 sites in United States, Belgium and 4 more
- Volunteers
- 107 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Pharmacokinetic Study of Dapivirine Vaginal Rings in Belgium
IPM 018 is a double-blind, randomized, placebo-controlled study conducted at one site in Belgium among 24 healthy, HIV-negative women to evaluate dapivirine release for 28 days from matrix and reservoir intravaginal rings, each…
- Trial name
- NCT00469768
- Testing
- dapivirine reservoir intravaginal ring, dapivirine matrix intravaginal ring
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV/AIDS
Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients
AELIX-003 study aims to investigate the safety, tolerability, immunogenicity and efficacy of a regimen containing AELIX Therapeutics' HTI T-cell vaccines and Gilead´s Toll-Like Receptor 7 (TLR7) agonist vesatolimod in…
- Trial name
- AELIX-003 (NCT04364035)
- Testing
- ChAdOx1.HTI, MVA.HTI, GS-9620
- Where
- 9 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Aelix Therapeutics
HIV Infections
A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in…
- Trial name
- NCT00002428
- Testing
- HIV-1 Peptide Vaccine, Microparticulate Monovalent, rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical
Pharmacokinetics, Safety Issues
PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel
A double-blind, randomized trial (1:1) to characterize the local and systemic pharmacokinetics (PK) of two DPV-LNG vaginal ring formulations
- Conditions
- Pharmacokinetics, Safety Issues, Bleeding
- Trial name
- NCT05041699
- Testing
- IPM Ring-105, IPM Ring-106
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV Infections
Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data
The question that prompted this study is the extent to which results from clinical trials can be translated into everyday practice (external validity).
- Trial name
- NCT01134939
- Where
- 34 sites in Germany
- Volunteers
- 265 people
- Sponsor
- Boehringer Ingelheim
Human Immunodeficiency Virus (HIV) Infection
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
The purpose of this study is to assess whether a dosing adjustment is needed in patients with renal impairment.
- Trial name
- NCT00717067
- Testing
- Maraviroc, Ritonavir, Saquinavir
- Where
- 2 sites in Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study
This study (POLAR), is designed to assess the antiviral activity and safety of CAB LA plus RPV LA, administered Q2M, in approximately 100 adult HIV-1 infected, antiretroviral therapy (ART) experienced participants.
- Trial name
- NCT03639311
- Testing
- CAB LA, RPV LA, RPV
- Where
- 30 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- ViiV Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.